An announcement from Tigermed (HKEX: 03347) reveals that as of June 16, 2026, the company has repurchased a total of 17.783 million of its own A-shares through a dedicated securities account for share buybacks, using the method of centralized competitive bidding.

The repurchased shares represent approximately 2.0654% of the company's current total share capital and about 2.4100% of its current total A-share capital.

The highest price paid per share was 39.96 yuan, while the lowest price was 38.22 yuan. The total transaction value amounted to 698.9 million yuan, excluding associated trading fees.

The execution of this buyback program is reported to be in full compliance with the company's approved share repurchase plan and the relevant legal and regulatory requirements.